Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Paediatric outcomes after maternal nipocalimab for haemolytic disease of the fetus and newborn: an open-label, single-arm study.
Journal: Archives of disease in childhood. Fetal and neonatal edition
Published: June 04, 2026
Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn.
Journal: NEJM evidence
Published: January 27, 2026
Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn.
Journal: American journal of perinatology
Published: March 06, 2025
Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn.
Journal: American journal of perinatology
Published: August 28, 2024
Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn.
Journal: The New England journal of medicine
Published: August 08, 2024
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: March 08, 2024
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases.
Journal: Journal of clinical immunology
Published: January 09, 2024
Showing 1-7 of 7
Last Updated: 09/26/2026